Logo image of PGNY

PROGYNY INC (PGNY) Stock Fundamental Analysis

USA - NASDAQ:PGNY - US74340E1038 - Common Stock

20 USD
-0.19 (-0.94%)
Last: 10/7/2025, 8:00:01 PM
20 USD
0 (0%)
After Hours: 10/7/2025, 8:00:01 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to PGNY. PGNY was compared to 101 industry peers in the Health Care Providers & Services industry. Both the health and profitability get an excellent rating, making PGNY a very profitable company, without any liquidiy or solvency issues. PGNY has a correct valuation and a medium growth rate. These ratings would make PGNY suitable for quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

PGNY had positive earnings in the past year.
PGNY had a positive operating cash flow in the past year.
In the past 5 years PGNY has always been profitable.
In the past 5 years PGNY always reported a positive cash flow from operatings.
PGNY Yearly Net Income VS EBIT VS OCF VS FCFPGNY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

The Return On Assets of PGNY (6.98%) is better than 88.12% of its industry peers.
With a decent Return On Equity value of 10.31%, PGNY is doing good in the industry, outperforming 74.26% of the companies in the same industry.
The Return On Invested Capital of PGNY (10.87%) is better than 82.18% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PGNY is in line with the industry average of 9.20%.
The 3 year average ROIC (8.25%) for PGNY is below the current ROIC(10.87%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.98%
ROE 10.31%
ROIC 10.87%
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
PGNY Yearly ROA, ROE, ROICPGNY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

The Profit Margin of PGNY (4.28%) is better than 73.27% of its industry peers.
PGNY's Profit Margin has declined in the last couple of years.
PGNY has a Operating Margin of 6.18%. This is in the better half of the industry: PGNY outperforms 63.37% of its industry peers.
In the last couple of years the Operating Margin of PGNY has grown nicely.
PGNY has a Gross Margin of 22.34%. This is comparable to the rest of the industry: PGNY outperforms 45.54% of its industry peers.
PGNY's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 6.18%
PM (TTM) 4.28%
GM 22.34%
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
PGNY Yearly Profit, Operating, Gross MarginsPGNY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

More info and screens

9

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PGNY is still creating some value.
PGNY has less shares outstanding than it did 1 year ago.
PGNY has more shares outstanding than it did 5 years ago.
PGNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PGNY Yearly Shares OutstandingPGNY Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
PGNY Yearly Total Debt VS Total AssetsPGNY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 7.07 indicates that PGNY is not in any danger for bankruptcy at the moment.
PGNY has a Altman-Z score of 7.07. This is amongst the best in the industry. PGNY outperforms 90.10% of its industry peers.
There is no outstanding debt for PGNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.07
ROIC/WACC1.19
WACC9.1%
PGNY Yearly LT Debt VS Equity VS FCFPGNY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

PGNY has a Current Ratio of 2.70. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
PGNY's Current ratio of 2.70 is amongst the best of the industry. PGNY outperforms 82.18% of its industry peers.
PGNY has a Quick Ratio of 2.70. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
PGNY has a Quick ratio of 2.70. This is amongst the best in the industry. PGNY outperforms 82.18% of its industry peers.
Industry RankSector Rank
Current Ratio 2.7
Quick Ratio 2.7
PGNY Yearly Current Assets VS Current LiabilitesPGNY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

PGNY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.35%.
Measured over the past years, PGNY shows a decrease in Earnings Per Share. The EPS has been decreasing by -4.77% on average per year.
Looking at the last year, PGNY shows a quite strong growth in Revenue. The Revenue has grown by 9.62% in the last year.
Measured over the past years, PGNY shows a very strong growth in Revenue. The Revenue has been growing by 38.42% on average per year.
EPS 1Y (TTM)-6.35%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%11.76%
Revenue 1Y (TTM)9.62%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%9.47%

3.2 Future

PGNY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.47% yearly.
PGNY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.86% yearly.
EPS Next Y10.72%
EPS Next 2Y34.66%
EPS Next 3Y31.82%
EPS Next 5Y32.47%
Revenue Next Year9.74%
Revenue Next 2Y9.58%
Revenue Next 3Y10.09%
Revenue Next 5Y8.86%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PGNY Yearly Revenue VS EstimatesPGNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
PGNY Yearly EPS VS EstimatesPGNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0.5 1 1.5 2 2.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 33.90 indicates a quite expensive valuation of PGNY.
PGNY's Price/Earnings ratio is in line with the industry average.
The average S&P500 Price/Earnings ratio is at 27.76. PGNY is valued slightly more expensive when compared to this.
With a Price/Forward Earnings ratio of 19.35, PGNY is valued on the expensive side.
Based on the Price/Forward Earnings ratio, PGNY is valued a bit cheaper than the industry average as 63.37% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of PGNY to the average of the S&P500 Index (23.21), we can say PGNY is valued inline with the index average.
Industry RankSector Rank
PE 33.9
Fwd PE 19.35
PGNY Price Earnings VS Forward Price EarningsPGNY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

PGNY's Enterprise Value to EBITDA ratio is in line with the industry average.
87.13% of the companies in the same industry are more expensive than PGNY, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 9.04
EV/EBITDA 15.37
PGNY Per share dataPGNY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of PGNY may justify a higher PE ratio.
PGNY's earnings are expected to grow with 31.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.16
PEG (5Y)N/A
EPS Next 2Y34.66%
EPS Next 3Y31.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PGNY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROGYNY INC

NASDAQ:PGNY (10/7/2025, 8:00:01 PM)

After market: 20 0 (0%)

20

-0.19 (-0.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)10-30 2025-10-30/amc
Inst Owners104.25%
Inst Owner Change0%
Ins Owners1.34%
Ins Owner Change0.04%
Market Cap1.72B
Analysts80
Price Target29.29 (46.45%)
Short Float %8.65%
Short Ratio6.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.43%
Min EPS beat(2)-11.77%
Max EPS beat(2)14.63%
EPS beat(4)2
Avg EPS beat(4)-0.31%
Min EPS beat(4)-19.12%
Max EPS beat(4)15%
EPS beat(8)5
Avg EPS beat(8)9.53%
EPS beat(12)9
Avg EPS beat(12)48.1%
EPS beat(16)13
Avg EPS beat(16)104.01%
Revenue beat(2)2
Avg Revenue beat(2)2.57%
Min Revenue beat(2)1.96%
Max Revenue beat(2)3.19%
Revenue beat(4)3
Avg Revenue beat(4)1.39%
Min Revenue beat(4)-5.35%
Max Revenue beat(4)5.74%
Revenue beat(8)4
Avg Revenue beat(8)-0.57%
Revenue beat(12)7
Avg Revenue beat(12)0.46%
Revenue beat(16)8
Avg Revenue beat(16)-0.53%
PT rev (1m)0%
PT rev (3m)7.49%
EPS NQ rev (1m)11.27%
EPS NQ rev (3m)21.18%
EPS NY rev (1m)2.64%
EPS NY rev (3m)14.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.93%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)2.8%
Valuation
Industry RankSector Rank
PE 33.9
Fwd PE 19.35
P/S 1.38
P/FCF 9.04
P/OCF 8.51
P/B 3.34
P/tB 3.52
EV/EBITDA 15.37
EPS(TTM)0.59
EY2.95%
EPS(NY)1.03
Fwd EY5.17%
FCF(TTM)2.21
FCFY11.06%
OCF(TTM)2.35
OCFY11.75%
SpS14.44
BVpS5.99
TBVpS5.68
PEG (NY)3.16
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 6.98%
ROE 10.31%
ROCE 14.2%
ROIC 10.87%
ROICexc 24.96%
ROICexgc 28.14%
OM 6.18%
PM (TTM) 4.28%
GM 22.34%
FCFM 15.31%
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
ROICexc(3y)19.18%
ROICexc(5y)17.15%
ROICexgc(3y)20.6%
ROICexgc(5y)18.86%
ROCE(3y)10.79%
ROCE(5y)10.01%
ROICexcg growth 3Y11.16%
ROICexcg growth 5Y-10.91%
ROICexc growth 3Y11.54%
ROICexc growth 5Y-2.19%
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
F-Score8
Asset Turnover1.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 293.7%
Cap/Sales 0.95%
Interest Coverage 250
Cash Conversion 250.02%
Profit Quality 358.02%
Current Ratio 2.7
Quick Ratio 2.7
Altman-Z 7.07
F-Score8
WACC9.1%
ROIC/WACC1.19
Cap/Depr(3y)177.5%
Cap/Depr(5y)150.16%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.39%
Profit Quality(3y)290.66%
Profit Quality(5y)196.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-6.35%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%11.76%
EPS Next Y10.72%
EPS Next 2Y34.66%
EPS Next 3Y31.82%
EPS Next 5Y32.47%
Revenue 1Y (TTM)9.62%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%9.47%
Revenue Next Year9.74%
Revenue Next 2Y9.58%
Revenue Next 3Y10.09%
Revenue Next 5Y8.86%
EBIT growth 1Y7.81%
EBIT growth 3Y27.82%
EBIT growth 5Y41.01%
EBIT Next Year33.19%
EBIT Next 3Y18.12%
EBIT Next 5Y15.38%
FCF growth 1Y14.92%
FCF growth 3Y93.67%
FCF growth 5YN/A
OCF growth 1Y19.24%
OCF growth 3Y90.18%
OCF growth 5YN/A